CTXR vs. CVKD, INKT, ANVS, ALLK, OKUR, KZR, GBIO, SRZN, CALC, and CYCC
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Cadrenal Therapeutics (CVKD), MiNK Therapeutics (INKT), Annovis Bio (ANVS), Allakos (ALLK), OnKure Therapeutics (OKUR), Kezar Life Sciences (KZR), Generation Bio (GBIO), Surrozen (SRZN), CalciMedica (CALC), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical products" industry.
Citius Pharmaceuticals vs.
Citius Pharmaceuticals (NASDAQ:CTXR) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 2 mentions for Citius Pharmaceuticals. Cadrenal Therapeutics' average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.75 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.
Citius Pharmaceuticals presently has a consensus price target of $54.50, indicating a potential upside of 7,902.94%. Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 103.82%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Citius Pharmaceuticals is more favorable than Cadrenal Therapeutics.
Citius Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.
Citius Pharmaceuticals received 206 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 62.65% of users gave Citius Pharmaceuticals an outperform vote.
Citius Pharmaceuticals' return on equity of -51.69% beat Cadrenal Therapeutics' return on equity.
16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 12.1% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Citius Pharmaceuticals beats Cadrenal Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CTXR) was last updated on 5/22/2025 by MarketBeat.com Staff
